Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3012% above fair value
$9.37+0.06 (+0.64%)
Close on Nov 13, 2026Market cap $799.39MP/E –Yield –
Monte Rosa Therapeutics statistics
79 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Mar 16, 2027 (estimated, before the open)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 1.61
- 2.22
Enterprise valuationIndustry
- EV / Sales
- 3.15
- 2.57
Share statisticsIndustry
- Shares Change (YoY)
- 19.3%
- 10.8%
- Shares Change (QoQ)
- 0.24%
- 0.50%
- Float
- 75M
- 49M
- Shares Held by Insiders
- 11.5%
- 11.7%
- Shares Held by Institutions
- 109.4%
- 56.4%
Short sellingIndustry
- Short Interest
- 21M
- –
- Short Interest Change
- 0.95%
- -0.80%
- Short % of Float
- 27.6%
- 9.01%
- Short % of Shares Outstanding
- 24.4%
- 6.30%
- Days to Cover
- 15.68
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $25.77
- –
- 52-Week Low
- $8.95
- –
- 20-Day Moving Average
- $10.58
- –
- 50-Day Moving Average
- $11.30
- –
- 200-Day Moving Average
- $16.74
- –
- Average True Range (14)
- $0.64
- –
- Price Change (1 Week)
- -11.4%
- -1.15%
- Price Change (1 Month)
- -7.41%
- -4.87%
- Price Change (3 Months)
- -39.1%
- -21.0%
- Price Change (6 Months)
- -48.4%
- -20.6%
- Price Change (YTD)
- -40.2%
- -23.6%
- Price Change (1 Year)
- -33.8%
- -22.4%
- Price Change (3 Years)
- 174.8%
- -29.5%
- Price Change (5 Years)
- -62.8%
- -77.9%
- Average Volume (10 Days)
- 1M
- –
- Average Volume (20 Days)
- 1M
- –
- Average Volume (90 Days)
- 1M
- –
- Relative Volume
- 0.82
- 0.70
- Relative Strength Index (14)
- 33.4
- 43.4
- Volatility (1 Year)
- 80.0%
- 80.1%
- Beta (5 Years)
- 1.82
- 1.07
MarginsIndustry
- Pretax Margin
- -184.8%
- -11.6%
- EBITDA Margin
- -214.5%
- -27.7%
- FCF Margin
- -248.0%
- -9.56%
Returns on capitalIndustry
- Return on Equity (ROE)
- -35.3%
- -49.9%
- Return on Assets (ROA)
- -22.6%
- -40.6%
- Return on Capital Employed (ROCE)
- -23.7%
- -37.9%
Financial positionIndustry
- Current Ratio
- 10.32
- 3.30
- Quick Ratio
- 9.31
- 2.39
GrowthIndustry
- Revenue Growth (YoY)
- -61.3%
- 6.82%
- Net Income Growth (YoY)
- -725.2%
- -14.4%
- EPS Growth (YoY)
- -660.0%
- -12.3%
- FCF Growth (YoY)
- -220.3%
- 6.85%
EfficiencyIndustry
- Asset Turnover
- 0.12
- 0.40
- Revenue Per Employee
- $468.83K
- $429.29K
- Profits Per Employee
- -$872.97K
- -$689.41K
- Employee Count
- 150
- 74
- WACC
- 14.2%
- 10.2%
Income statement (TTM)Industry
- Pretax Income
- -$129.94M
- -$12.95M
Balance sheetIndustry
- Net Cash (Debt)
- $577.70M
- $17.76M
- Net Cash Per Share
- $6.77
- $0.80
- Equity (Book Value)
- $496.21M
- $53.89M
- Book Value Per Share
- $5.82
- $1.50
- Tangible Book Value
- $496.21M
- $27.13M
- Working Capital
- $578.02M
- $79.99M
Cash flow (TTM)Industry
- Capital Expenditures
- -$8.92M
- -$1.00M
- FCF Per Share
- -$2.04
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -16.4%
- -21.8%
- FCF Yield
- -21.8%
- -9.44%
Taxes and interestIndustry
- Income Tax
- $1.04M
- $73.00K
Scores and fair valueIndustry
- Altman Z-Score
- 1.63
- 0.23
- Piotroski F-Score
- 5
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | GLUE | S&P 500 | Difference | GLUE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.3% | -3.0% | −2.2 pts | ||
| 3 months | -40.8% | -2.8% | −38.1 pts | ||
| Year to date | -40.2% | +11.5% | −51.7 pts | ||
| 1 year | -34.6% | +13.5% | −48.0 pts | ||
| 3 years | +206.7% | +77.7% | +129.0 pts | +45.3% | +21.1% |
| 5 years | -62.8% | +72.6% | −135.4 pts | -17.9% | +11.5% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
21M GLUE shares were sold short on Oct 30, 2026, up 0.9% from the previous report, or 27.63% of the shares available to trade. At recent volumes it would take 15.7 days to buy them back. Over the last 20 sessions, 61.3% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 20,856,472 | +0.9% | 1,329,898 | 15.7 |
| Oct 15, 2026 | 20,660,257 | +4.9% | 1,837,865 | 11.2 |
| Sep 30, 2026 | 19,686,241 | +2.2% | 1,093,381 | 18.0 |
| Sep 15, 2026 | 19,265,990 | +6.6% | 1,127,772 | 17.1 |
| Aug 31, 2026 | 18,075,786 | +3.5% | 1,091,293 | 16.6 |
| Aug 14, 2026 | 17,457,317 | +6.1% | 1,247,991 | 14.0 |
| Jul 31, 2026 | 16,458,543 | -4.3% | 1,554,197 | 10.6 |
| Jul 15, 2026 | 17,195,471 | -7.7% | 1,314,790 | 13.1 |
| Jun 30, 2026 | 18,634,735 | +8.5% | 2,195,951 | 8.5 |
| Jun 15, 2026 | 17,170,729 | +7.3% | 1,033,043 | 16.6 |
| May 29, 2026 | 16,005,122 | +7.0% | 832,953 | 19.2 |
| May 15, 2026 | 14,962,299 | -1.2% | 725,334 | 20.6 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?